RecruitingPhase 1NCT06234423

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

A Phase 1, First-in-Human Study of CUSP06, a Cadherin-6 (CDH6)-Directed Antibody-Drug Conjugate, in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

Sponsor

OnCusp Therapeutics, Inc.

Enrollment

263 participants

Start Date

Feb 9, 2024

Study Type

INTERVENTIONAL

Conditions

Ovarian Cancer Solid Tumor

Summary

This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This early-phase trial is testing a new drug called CUSP06 for patients with platinum-resistant or platinum-refractory ovarian cancer, as well as other advanced solid tumors that have stopped responding to standard treatments. **You may be eligible if...** - You are 18 years or older - You have advanced cancer (confirmed by biopsy) that has progressed after standard therapy - Your cancer is measurable on scans - You are in reasonably good general health - Your blood counts, kidney, liver, and heart function are within acceptable ranges **You may NOT be eligible if...** - You have uncontrolled brain metastases - Your general health status is poor - You have significant kidney, liver, or heart problems that fall below the required thresholds - You are unable or unwilling to provide a tumor tissue sample Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCUSP06

Antibody drug conjugate (ADC)

Locations(15)

Sarah Cannon Research Institute at HealthONE

Denver, Colorado, United States

Yale University

New Haven, Connecticut, United States

Mount Sinai Medical Center

Miami Beach, Florida, United States

Florida Cancer Specialists

Sarasota, Florida, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

START Midwest

Grand Rapids, Michigan, United States

NYU Cancer Institute Clinical Cancer Center

New York, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Stephenson Cancer Center

Oklahoma City, Oklahoma, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

NEXT Oncology

Houston, Texas, United States

START San Antonio

San Antonio, Texas, United States

NEXT Oncology

Fairfax, Virginia, United States

Mater Cancer Care Centre

South Brisbane, Queensland, Australia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06234423

Related Trials

NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors

NCT074893781 location

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

NCT0731855828 locations

DESTINY-PANTUMOUR04

NCT0712400017 locations

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

NCT067605071 location

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467164 locations